Stephen Natoli

Feb 16, 2024 | outsourcedpharma.com | Louis Garguilo |Mark Witcher |Yves Massicotte |Stephen Natoli

Novo Holdings has responded directly to our request for a more definitive disposition of Catalent once it is acquired by the private investment company Novo Nordisk. The quick reply is fortuitous; competitors are circling. Relational Risk Analysis For The Biopharma IndustrySuccessfully developing and manufacturing biopharmaceuticals depends on identifying, analyzing, and managing a wide variety of risks.